Additionally, a randomized, placebo-controlled phase 2a trial investigating brepocitinib, a tyrosine kinase 2/Janus kinase 1 inhibitor (45 mg/day), in 37 patients with FFA, LPP, or centrifugal cicatricial alopecia showed a significant reduction in clinical severity scores across all cicatricial alopecia subtypes through week 48 [58]. This evidence concerns the gene JAK1 and cicatricial alopecia.